5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells - 22/03/08


pages | 6 |
Iconographies | 3 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Vascular endothelial growth factor (VEGF) is involved in angiogenesis, growth, and tumour cell metastasis. VEGF is expressed as alternative splice variants, which exhibit angiogenic and anti-angiogenic properties. We determined the effect of 5-Aza-2'-deoxycytidine (5-dAzaC) DNA methyltransferase (DNMTs) inhibitor on angiogenic and anti-angiogenic VEGF variants expression in immortalized human lung microvascular endothelial cells (HLMEC). Employing reverse transcription, real-time quantitative PCR (RQ-PCR), and Western blot analysis, we determined that 5-dAzaC decreased VEGF121a and VEGF165a angiogenic, and VEGF121b and VEGF165b anti-angiogenic variants expression in HLMEC. However, this DNMTs inhibitor significantly increases expression of VEGF189b anti-angiogenic variant transcript and protein in HLMEC. Our results suggest that the DNMTs activity may have an influence on the expression of angiogenic and anti-angiogenic VEGF variants in human lung microvascular endothelial cells.
Le texte complet de cet article est disponible en PDF.Keywords : Vascular endothelial growth factor, Epigenetic regulation, Angiogenesis
Plan
Vol 62 - N° 3
P. 158-163 - mars 2008 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?